Loading...
We would love for you to become a part of our community. Join our Discord to connect with us and other members!
- Ticker
- ABOS
- Price
- 1.90
- Stock movement up
- +0.05 (2.70%)
- Company name
- Acumen Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 114.15M
- Ent value
- 130.74M
- Price/Sales
- 393.63
- Price/Book
- 0.53
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -51.78%
- 3 year return
- -34.94%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-01-03
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ABOS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 393.63 |
| Price to Book | 0.53 |
| EV to Sales | 450.83 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 60.08M |
| EPS (TTM) | -1.36 |
| FCF per share (TTM) | -1.12 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 290.00K |
| Gross profit (TTM) | 162.00K |
| Operating income (TTM) | -92.91M |
| Net income (TTM) | -81.67M |
| EPS (TTM) | -1.36 |
| EPS (1y forward) | -1.53 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 55.86% |
| Operating margin (TTM) | -32036.55% |
| Profit margin (TTM) | -28162.76% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 33.18M |
| Net receivables | 0.00 |
| Total current assets | 207.63M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 266.98M |
| Accounts payable | 2.34M |
| Short/Current long term debt | 29.99M |
| Total current liabilities | 19.91M |
| Total liabilities | 49.77M |
| Shareholder's equity | 217.20M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -67.31M |
| Capital expenditures (TTM) | 30.00K |
| Free cash flow (TTM) | -67.34M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -37.60% |
| Return on Assets | -30.59% |
| Return on Invested Capital | -37.58% |
| Cash Return on Invested Capital | -30.99% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.90 |
| Daily high | 1.93 |
| Daily low | 1.76 |
| Daily Volume | 359K |
| All-time high | 20.28 |
| 1y analyst estimate | 10.80 |
| Beta | 0.04 |
| EPS (TTM) | -1.36 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 24 Mar 2025 |
Downside potential
Loading...
Downside potential data
| ABOS | S&P500 | |
| Current price drop from All-time high | -90.63% | -2.61% |
| Highest price drop | -91.52% | -56.47% |
| Date of highest drop | 31 Dec 2024 | 9 Mar 2009 |
| Avg drop from high | -71.67% | -11.12% |
| Avg time to new high | 883 days | 12 days |
| Max time to new high | 882 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
114.15M
Marketcap category
Small-cap
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Employees
51
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page